Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT06309394
- Locations
- 🇬🇧
Quotient Sciences Ltd, Nottingham, United Kingdom
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 958
- Registration Number
- NCT06259669
- Locations
- 🇺🇸
Syneos Health (remote site), Morrisville, North Carolina, United States
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 225
- Registration Number
- NCT06238817
- Locations
- 🇮🇹
Irccs Istituto Clinico Humanitas, Rozzano, Italy
🇫🇷Chu de Rouen - Hospital Charles Nicolle, Rouen, France
🇩🇪Universitatsklinikum Munster, Muenster, Germany
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 180
- Registration Number
- NCT06213818
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 960
- Registration Number
- NCT06212999
- Locations
- 🇪🇸
Investigative Site ES301, Granada, Spain
🇩🇪Investigative Site DE301, Frankfurt, Germany
🇩🇪Investigative Site DE208, Goettingen, Germany
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06213831
- Locations
- 🇺🇸
Equity Medical, Llc, New York, New York, United States
🇺🇸Saguaro Dermatology, Phoenix, Arizona, United States
🇺🇸Affiliated Dermatology, Scottsdale, Arizona, United States
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 466
- Registration Number
- NCT06179160
- Locations
- 🇪🇸
Fundacion Jimenez Diaz, Madrid, Spain
🇺🇸Scri Oncology Partners, Nashville, Tennessee, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
- Conditions
- NonSegmental Vitiligo
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 450
- Registration Number
- NCT06113471
- Locations
- 🇨🇦
Research Toronto, Toronto, Ontario, Canada
🇨🇦Centre de Recherche Dermatologique de Quebec, Quebec City, Quebec, Canada
🇫🇷Chru Morvan/Chu Brest Hopital Morvan, Brest, France
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
- Conditions
- NonSegmental Vitiligo
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 467
- Registration Number
- NCT06113445
- Locations
- 🇺🇸
Revival Research Institute, Llc Dermatology, Troy, Michigan, United States
🇺🇸Medisearch Clinical Trials, Saint Joseph, Missouri, United States
🇺🇸Jdr Dermatology Research, Las Vegas, Nevada, United States
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT06039384
- Locations
- 🇮🇹
Fondazione Del Piemonte Per L Oncologia Ircc Candiolo, Candiolo, Italy
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Banner Md Anderson Cancer Center, Greeley, Colorado, United States